Milan, Italy, 24 September 2024:
Aptadir Therapeutics is pioneering a revolutionary approach in the realm of biotechnology with its innovative RNA inhibitor-based therapies. The biotech startup has recently announced a significant breakthrough that could reshape treatment strategies for intractable cancers and genetic conditions.
Breaking new ground with RNA Inhibitors
Aptadir’s research centers on RNA inhibitors, specifically designed to tackle diseases with previously limited treatment options. Their unique approach involves DiRs (DNMTs Interacting RNAs), a new class of RNA inhibitors capable of selectively reactivating hypermethylated genes. This method shows immense potential for targeting the root causes of diseases such as Myelodysplastic Syndrome (MDS) in adults and Fragile X Syndrome in children—conditions known for their complexity and resistance to traditional treatments.
The foundation of Aptadir’s technology is based on significant scientific discoveries made at prestigious institutions such as Harvard Medical School, the Cancer Science Institute of Singapore, and Italy’s CNR Institute. The company’s cutting-edge science is the product of the collaborative efforts of renowned experts like Dr. Annalisa Di Ruscio, Dr. Vittorio De Franciscis, Prof. Daniel Tenen, and Prof. Marcin Kortylewski.
The road ahead
With Giovanni Amabile at the helm as the Executive Chairman and acting CEO, Aptadir is gearing up to navigate the future challenges in biomedicine. The company is poised to advance its leading program, Aptadir Ce-49, towards clinical trials by the end of 2025, aiming to establish a new standard in the treatment of complex genetic disorders.
Aptadir’s launch was bolstered by an impressive $1.6 million in pre-seed funding from EXTEND (EXTEND is the third National Technology Transfer Hub launched by CDP Venture Capital SGR through its Technology Transfer Fund with Angelini Ventures and Evotec) earmarked for optimizing its leading asset, Aptadir Ce-49. This initial financial injection is just the beginning, as the company eyes further development and commercialization of its platform.
Stay tuned for more updates on Aptadir’s journey and breakthroughs in the field of biotech innovations.